Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
Want to see GPCR full AI Analyst Report?
Top Page
Structure Therapeutics, Inc. Sponsored ADR
(NASDAQ:GPCR)
Select Model
Select Model
Rating:50Neutral
Price Target:
$39.00
▼(-23.15% Downside)
Action:Reiterated
Date:05/09/26
The score is held near the middle primarily by mixed financial fundamentals (strong balance sheet but ongoing large losses and cash burn) and weak technicals (below key moving averages with bearish MACD). Positive corporate developments in the obesity program and improved financing flexibility provide an offset, but negative earnings and cash flow limit the overall rating.
Positive Factors
Strong balance sheet and liquidity
A large equity base and negligible leverage give Structure Therapeutics multi-year funding flexibility to support late-stage programs without immediate solvency pressure. This durable financial cushion allows continued R&D investment and reduces the likelihood of forced distressed financings while trials progress.
Negative Factors
Pre-revenue with widening operating losses
As a pre-revenue biotech with expanding operating losses, the company remains dependent on successful clinical outcomes to generate future revenue. Persistent negative earnings elevate execution risk and mean long-term investor returns hinge heavily on trial success and commercialization timing.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet and liquidity
A large equity base and negligible leverage give Structure Therapeutics multi-year funding flexibility to support late-stage programs without immediate solvency pressure. This durable financial cushion allows continued R&D investment and reduces the likelihood of forced distressed financings while trials progress.
Read all positive factors
Structure Therapeutics, Inc. Sponsored ADR (GPCR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.81B
Dividend YieldN/A
Average Volume (3M)831.22K
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue GrowthN/A
EPS Growth-4.45%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.64
Shares Outstanding71,074,520
10 Day Avg. Volume691,542
30 Day Avg. Volume831,224
Financial Highlights & Ratios
PEG Ratio-11.37
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.64K
Enterprise Value/Ebitda-10.52
Forecast
1Y Price Target
$111.50Price Target Upside119.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.4
Revenue Forecast (FY)$37.50M
Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model
Company Description
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biase...
How the Company Makes Money
Revenue information that clearly specifies how Structure Therapeutics currently makes money (e.g., product sales, recurring service revenue, or disclosed material collaboration/licensing income) is not available in the provided prompt. null...
Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.22M | -3.90M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -190.31M | -136.79M | -157.24M | -102.48M | -52.28M | -37.62M |
| Net Income | -170.56M | -141.20M | -122.53M | -89.62M | -51.32M | -40.01M |
Balance Sheet | ||||||
| Total Assets | 1.51B | 1.58B | 903.33M | 482.02M | 97.84M | 111.16M |
| Cash, Cash Equivalents and Short-Term Investments | 1.46B | 1.45B | 883.52M | 467.32M | 90.84M | 107.31M |
| Total Debt | 5.79M | 6.49M | 3.86M | 5.45M | 260.00K | 621.00K |
| Total Liabilities | 61.03M | 67.54M | 38.49M | 29.05M | 212.99M | 175.89M |
| Stockholders Equity | 1.45B | 1.52B | 864.84M | 452.97M | -115.14M | -64.73M |
Cash Flow | ||||||
| Free Cash Flow | -159.18M | -225.81M | -117.93M | -81.66M | -46.27M | -33.37M |
| Operating Cash Flow | -154.69M | -222.20M | -116.64M | -79.49M | -46.12M | -32.16M |
| Investing Cash Flow | -442.67M | 89.80M | -358.91M | -268.34M | -62.11M | 17.86M |
| Financing Cash Flow | 759.96M | 762.52M | 515.26M | 451.53M | 29.01M | 103.25M |
Structure Therapeutics, Inc. Sponsored ADR Technical Analysis
Neutral
50.75
Price Trends
45.69
Negative
59.23
Negative
46.48
Negative
Market Momentum
-2.39
Negative
42.15
Neutral
74.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Neutral. The current price of 50.75 is above the 20-day moving average (MA) of 39.35, above the 50-day MA of 45.69, and above the 200-day MA of 46.48, indicating a neutral trend. The MACD of -2.39 indicates Negative momentum. The RSI at 42.15 is Neutral, neither overbought nor oversold. The STOCH value of 74.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GPCR.
Structure Therapeutics, Inc. Sponsored ADR Risk Analysis
Structure Therapeutics, Inc. Sponsored ADR disclosed 103 risk factors in its most recent earnings report. Structure Therapeutics, Inc. Sponsored ADR reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Structure Therapeutics, Inc. Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.82B | -18.53 | -0.25% | ― | -12.98% | 8.99% | |
50 Neutral | $2.81B | -17.06 | -15.14% | ― | ― | -4.45% | |
49 Neutral | $1.74B | -7.03 | -256.66% | ― | 397.28% | 27.68% | |
49 Neutral | $1.96B | -11.74 | -48.84% | ― | -83.20% | -439.48% |
* Healthcare Sector Average
GPCR
Structure Therapeutics, Inc. Sponsored ADR
40.17
17.75
79.17%
SNDX
Syndax Pharmaceuticals
19.75
9.13
85.97%
ZYME
Zymeworks
25.48
14.13
124.49%
STOK
Stoke Therapeutics
31.61
21.88
224.87%
Structure Therapeutics, Inc. Sponsored ADR Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Structure Therapeutics Expands ATM Capacity, Advances Obesity Program
Positive
May 7, 2026
On May 7, 2026, Structure Therapeutics amended and restated its at-the-market sales agreement with Leerink Partners and Cantor Fitzgerald, removing the cap on American Depositary Shares that can be issued and filing a prospectus supplement to lift...
Business Operations and StrategyExecutive/Board Changes
Structure Therapeutics Appoints Matthew Lang as Chief Operating Officer
Positive
Apr 15, 2026
On April 14, 2026, Structure Therapeutics announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel, bringing more than 15 years of executive leadership across global biopharmaceutical companies. Lang’s b...
Business Operations and StrategyProduct-Related Announcements
Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results
Positive
Mar 16, 2026
On March 16, 2026, Structure Therapeutics reported positive topline results from its Phase 2 ACCESS II trial of aleniglipron, showing statistically significant placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg over 44 weeks,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.